Emerging Immunotherapy Approaches for Treating Prostate Cancer
International Journal of Molecular Sciences · 20.09.2023 · 24 (18) · 14347
DOI: 10.3390/ijms241814347 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.09.2023. Verfasst von Lingbin Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antibodies, Bispecific, Biomedical Research. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 186 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
- Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.
ORCID-Profile: Lingbin Meng
Förderung
- NCI NIH HHS
Zitieren
APA
Meng, L., Yang, Y., Mortazavi, A., & Zhang, J. (2023). Emerging Immunotherapy Approaches for Treating Prostate Cancer. International Journal of Molecular Sciences, 24(18), 14347. https://doi.org/10.3390/ijms241814347
Vancouver
Meng L, Yang Y, Mortazavi A, Zhang J. Emerging Immunotherapy Approaches for Treating Prostate Cancer. International Journal of Molecular Sciences. 2023;24(18):14347. doi:10.3390/ijms241814347
BibTeX
@article{Meng2023,
author = {Meng, Lingbin and Yang, Yuanquan and Mortazavi, Amir and Zhang, Jingsong},
title = {Emerging Immunotherapy Approaches for Treating Prostate Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {18},
pages = {14347},
doi = {10.3390/ijms241814347}
}
EUVIMED